RECOMBINATE, [Antihemophilic Factor (Recombinant)], 5 mL vials, Rx Only, Takeda Pharmaceuticals USA, Cambridge, MA 02142, NDC: 00944-2843-01
Published August 13, 2025 · Recall initiated: July 30, 2025
Summary
FDA records drug Class II recall D-0573-2025, published August 13, 2025 and initiated July 30, 2025. Recalling firm: Cardinal Health Inc.; Status: Ongoing; Reported quantity: 3 units; Lot: Lot: TRB23802AC, Expires: 03/18/2026; TRA22804AA, Expires: 10/18/2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Cardinal Health Inc.
- Distributor
- Nationwide Within the U.S.
- Lot
- Lot: TRB23802AC, Expires: 03/18/2026; TRA22804AA, Expires: 10/18/2025
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAEnoxaparin Sodium Injection, USP, 30 mg/0.3 mL, packaged in 0.3 mL prefilled syringes further packaged in bagsSeptember 3, 2025
- FDAXolair (omalizumab injection), 150 mg/ml, 1 auto-injector, Rx only, Genentech, Inc, South San Francisco, CAAugust 13, 2025
- FDAXolair (omalizumab injection), 75 mg/0.5 ml, Rx only, Genentech, Inc., South San Francisco, CA 94080, NDCAugust 13, 2025
- FDASpironolactone Tablets, USP, 25 mg, 100-count bottle, Rx only, Mfg. by: Frontida BioPharm, Inc., 1100 OrthodoxAugust 13, 2025
- FDABrand Name: Queen Bee Gardens Whipped Honey Raspberry. Intended use: spread. Item is shelf stable. PackagingAugust 13, 2025
- FDAWegovy (semaglutide) injection, 2.4 mg/0.75 mL, 4 Single-Dose Prefilled Pens per Carton, For Subcutaneous UseMay 7, 2025
Questions about this recall
Was RECOMBINATE, [Antihemophilic Factor (Recombinant)], 5 mL vials, Rx Only, Takeda Pharmaceuticals USA, Cambridge, MA 02142, NDC: 00944-2843-01 recalled?
Yes. FDA published recall D-0573-2025 on August 13, 2025. Reported hazard: CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.
What should I do if I have this product?
Voluntary: Firm initiated · Letter